Comments on the renal aspects of the ALLHAT study
- 1 February 2003
- journal article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 21 (2) , 235-236
- https://doi.org/10.1097/00004872-200302000-00005
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney DiseaseResults From the AASK TrialJAMA, 2002
- The Kidney as a Sensor of Cardiovascular Risk in Essential HypertensionJournal of the American Society of Nephrology, 2002
- Prevalence of Low Glomerular Filtration Rate in Nondiabetic AmericansJournal of the American Society of Nephrology, 2002
- Chronic Renal Diseases: Renoprotective Benefits of Renin–Angiotensin System InhibitionAnnals of Internal Medicine, 2002
- Renal function: the Cinderella of cardiovascular risk profileJournal of the American College of Cardiology, 2001
- A random comparison of fosinopril and nifedipine GITS in patients with primary renal diseaseJournal Of Hypertension, 2001
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Characteristics of 15314 Hypertensive Patients at High Coronary Risk. The VALUE TrialBlood Pressure, 2001
- Rationale and Design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)American Journal of Hypertension, 1996